COYA
Coya Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.35 EPS, $102K rev
Last earnings -13.5% on 2026-05-12
$5.50
▲ +7.21%$5.50▼ -5.98%
over 1Y
L $3.94EODHDH $7.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.2%
1W+7.2%
1M+15.3%
3M+38.9%
YTD-2.7%
1Y-6.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Revenue grew 123.6% YoY; but unprofitable (net margin -267.1%).
Revenue (FY2025) $7.95M · FY2025
Coya Therapeutics, Inc. shows $7.95M in FY2025 revenue (+123.6% YoY), a -267.1% net margin, and -49.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $6.00M | $3.55M | $7.95M |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.87M | -$9.81M | -$7.90M | -$17.2M | -$22.6M |
| Net income | -$4.89M | -$12.2M | -$7.99M | -$14.9M | -$21.2M |
| Diluted EPS | -$1.89 | -$4.73 | -$0.79 | -$0.98 | -$1.27 |
| Net margin | — | — | -133.1% | -418.7% | -267.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$82.2M
EV / EBITDA—
EV / Sales10.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-16.5%
FCF yield—
Quality & risk
ROIC (est.)-41.4%
Free cash flow—
Total debt—
Net cash$46.8M
Altman Z-Score9.17 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+40.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Shareholder vote2026-06-25
- DEF 14A Proxy statement2026-05-13
- 8-K Material agreement2026-05-12
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K Officer / director change2026-04-02
- 8-K Earnings results2026-03-16
- S-3 Shelf registration (potential raise)2026-03-16
- 10-K Annual report2026-03-16
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-252026-06-25open ↗ARSPeriod ending 2025-12-312026-05-13open ↗DEFA14AFiling2026-05-13open ↗DEF 14APeriod ending 2026-06-252026-05-13open ↗8-KPeriod ending 2026-05-122026-05-12open ↗424B5Filing2026-05-12open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗4Period ending 2026-04-092026-04-09open ↗3Period ending 2026-04-012026-04-09open ↗8-KPeriod ending 2026-03-292026-04-02open ↗EFFECTFiling2026-03-20open ↗
Frequently asked
- Is Coya Therapeutics, Inc. (COYA) a buy?
- COYA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 123.6% YoY; but unprofitable (net margin -267.1%).
- What is Coya Therapeutics, Inc.'s quality score?
- COYA scores 40.058823529411754/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001835022, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:42:56 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.